Thyroid Cancer Research

Dr. Marcia Brose
Marcia Brose is Assistant Professor at the University of Pennsylvania School of Medicine, Philadelphia, PA, USA, in both the Departments of Otorhinolaryngology: Head and Neck Surgery and Medicine (Division of Hematology and Oncology). She received her medical degree from Weill Cornell Medical College and her PhD from the Rockefeller University, New York, USA. Dr Brose completed her specialty training in internal medicine, hematology and oncology at the Hospital of the University of Pennsylvania, before pursuing post-doctoral training in cancer genetics in the laboratory of Barbara Weber MD. She was then appointed as a faculty member at her current institution and concentrated her research on the genetics of head and neck cancers, with a particular focus on thyroid cancer.

Research
Dr. Brose is at the forefront of translational medicine and thyroid cancer research, working with the department of Otorhinolaryngology and the Abramson Cancer Center at the University of Pennsylvania. Her team of dedicated and highly trained physicians, scientists, research specialists and data managers are devoted to pursuing the highest quality clinical care and research to improve the diagnosis and treatment of people with thyroid cancer. The group pursues the immediate application of advances in scientific knowledge from lab work and from new literature to patient care in the clinic. Dr. Brose's ultimate aim is to directly improve diagnostic approaches and expand and advance novel treatments for patients with thyroid cancer at all stages.

Dr. Brose is currently focused on clinical trials at Penn which she designed herself and in the context of consortiums with colleagues from other institutions to improve the diagnosis and treatment of people with advanced thyroid cancer through the identification of novel treatments. She runs her own program on thyroid cancer therapeutics, and is the Principal Investigator of six phase I/II and III clinical trials.

Her Phase II trial using targeted therapy with sorafenib (BAYER/ONYX) to treat patients that have failed treatment for advanced thyroid cancer  have been extremely positive and has lead to an international, multicentered phase III trial of this agent for which she is again a Principle Investigator. Her results have shown slowing or stabilization of the disease in over 75% of participants for up to 25 months. The results of this Phase II trial are the first significant advance for the treatment of patients with advanced thyroid cancer in over 30 years. Dr Brose is a member of the American Association of Cancer Research, the American Head and Neck Society and the American Society of Clinical Oncology. She has received several prestigious awards, including the Damon Runyon Clinical Investigator award and the General Motors Cancer Research Foundation Research Scholar Award.